Russia to speed registration of drugs not localized in domestic market

12 September 2024

The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent.

According to an official spokesman of the Ministry, "taking into account the unpredictable geopolitical situation," accelerated registration of drugs that are not produced in the Russian Federation will be possible regardless of the current supply and balances of drugs in hospitals and pharmacies, as well as the volumes of their production.

In accordance with the current Russian legislation, drug registration in the case of a shortage or its risks should take no more than 60 working days from the date of submission of documents to the Ministry of Health. According to the ministry's latest draft, for drugs not localized in the country, these periods will not exceed 100 days from the date of submission of documents.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical